Andrea E Wahner Hendrickson, MD

  • 931 Citations
  • 15 Scopus h-Index
19982019

Research output per year

If you made any changes in Pure these will be visible here soon.

Research Output

Filter
Article
2019

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer

Hurley, R. M., Wahner Hendrickson, A. E., Visscher, D. W., Ansell, P., Harrell, M. I., Wagner, J. M., Negron, V., Goergen, K. M., Maurer, M. J., Oberg, A. L., Meng, X. W., Flatten, K. S., De Jonge, M. J. A., Van Herpen, C. D., Gietema, J. A., Koornstra, R. H. T., Jager, A., den Hollander, M. W., Dudley, M., Shepherd, S. P. & 2 others, Swisher, E. M. & Kaufmann, S. H., Apr 2019, In : Gynecologic oncology. 153, 1, p. 127-134 8 p.

Research output: Contribution to journalArticle

4 Scopus citations

Can Poly (ADP-Ribose) Polymerase Inhibitors Palliate Paclitaxel-Induced Peripheral Neuropathy in Patients With Cancer?

Balko, R. A., Wahner Hendrickson, A. E., Grudem, M. E., Klampe, C. M. & Jatoi, A., Jan 1 2019, In : American Journal of Hospice and Palliative Medicine. 36, 1, p. 72-75 4 p.

Research output: Contribution to journalArticle

2 Scopus citations

Loratadine for Paclitaxel-Induced Myalgias and Arthralgias

Smith, C., Wahner Hendrickson, A. E., Grudem, M., Klampe, C., Deering, E. & Jatoi, A., Jan 1 2019, (Accepted/In press) In : American Journal of Hospice and Palliative Medicine.

Research output: Contribution to journalArticle

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial

Moore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N., Fleming, G. F., Wahner Hendrickson, A. E., Azodi, M., DiSilvestro, P., Oza, A. M., Cristea, M., Berek, J. S., Chan, J. K., Rimel, B. J., Matei, D. E., Li, Y., Sun, K., Luptakova, K., Matulonis, U. A. & Monk, B. J., May 2019, In : The Lancet Oncology. 20, 5, p. 636-648 13 p.

Research output: Contribution to journalArticle

32 Scopus citations

Open-label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer

Vinayak, S., Tolaney, S. M., Schwartzberg, L., Mita, M., McCann, G., Tan, A. R., Wahner-Hendrickson, A. E., Forero, A., Anders, C., Wulf, G. M., Dillon, P., Lynce, F., Zarwan, C., Erban, J. K., Zhou, Y., Buerstatte, N., Graham, J. R., Arora, S., Dezube, B. J. & Telli, M. L., Aug 2019, In : JAMA Oncology. 5, 8, p. 1132-1140 9 p.

Research output: Contribution to journalArticle

15 Scopus citations
2018

A phase i clinical trial of the Poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors

Wahner Hendrickson, A. E., Menefee, M. E., Hartmann, L. C., Long, H. J., Northfelt, D. W., Reid, J. M., Boakye-Agyeman, F., Kayode, O., Flatten, K. S., Harrell, M. I., Swisher, E. M., Poirer, G. G., Satele, D., Allred, J., Lensing, J. L., Chen, A., Ji, J., Zang, Y., Erlichman, C., Haluska, P. & 1 others, Kaufmann, S. H., Feb 15 2018, In : Clinical Cancer Research. 24, 4, p. 744-752 9 p.

Research output: Contribution to journalArticle

11 Scopus citations
2 Scopus citations
2017
1 Scopus citations

Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancers

Colon-Otero, G., Weroha, S. J., Foster, N. R., Haluska, P., Hou, X., Wahner Hendrickson, A. E., Jatoi, A., Block, M. S., Dinh, T. A., Robertson, M. W. & Copland, J. A. III., Jul 1 2017, In : Gynecologic Oncology. 146, 1, p. 64-68 5 p.

Research output: Contribution to journalArticle

10 Scopus citations
2016

4EBP1/c-MYC/PUMA and NF-kB/EGR1/BIM pathways underlie cytotoxicity of mTOR dual inhibitors in malignant lymphoid cells

Yun, S., Vincelette, N. D., Knorr, K. L. B., Almada, L. L., Schneider, P. A., Peterson, K. L., Flatten, K. S., Dai, H., Pratz, K. W., Hess, A. D., Smith, B. D., Karp, J. E., Wahner Hendrickson, A. E., Fernandez-Zapico, M. E. & Kaufmann, S. H., Jun 2 2016, In : Blood. 127, 22, p. 2711-2722 12 p.

Research output: Contribution to journalArticle

27 Scopus citations

Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials

Yun, S., Vincelette, N. D., Green, M. R., Wahner Hendrickson, A. E. & Abraham, I., Jul 1 2016, In : Cancer Medicine. 5, 7, p. 1481-1491 11 p.

Research output: Contribution to journalArticle

34 Scopus citations
2014

A Mixed-Methods Feasibility Trial of Protein Kinase C Iota Inhibition with Auranofin in Asymptomatic Ovarian Cancer Patients

Jatoi, A., Radecki Breitkopf, C., Foster, N. R., Block, M. S., Grudem, M., Wahner Hendrickson, A. E., Carlson, R. E., Barrette, B., Karlin, N. & Fields, A. P., Dec 6 2014, (Accepted/In press) In : Oncology (Switzerland). p. 208-213 6 p.

Research output: Contribution to journalArticle

20 Scopus citations

Assessment of published models and prognostic variables in epithelial ovarian cancer at Mayo Clinic

Wahner Hendrickson, A. E., Hawthorne, K. M., Goode, E. L., Kalli, K. R., Goergen, K. M., Bakkum-Gamez, J. N., Cliby, W. A., Keeney, G., Visscher, D. W., Tarabishy, Y., Oberg, A. L., Hartmann, L. C. & Maurer, M. J., Dec 2 2014, (Accepted/In press) In : Gynecologic Oncology.

Research output: Contribution to journalArticle

10 Scopus citations
2013

ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status

Huntoon, C. J., Flatten, K. S., Wahner Hendrickson, A. E., Huehls, A. M., Sutor, S. L., Kaufmann, S. H. & Karnitz, L. M., Jun 15 2013, In : Cancer research. 73, 12, p. 3683-3691 9 p.

Research output: Contribution to journalArticle

94 Scopus citations

Phase i study of tanespimycin in combination with bortezomib in patients with advanced solid malignancies

Schenk, E., Hendrickson, A. E. W., Northfelt, D., Toft, D. O., Ames, M. M., Menefee, M., Satele, D., Qin, R. & Erlichman, C., Oct 1 2013, In : Investigational New Drugs. 31, 5, p. 1251-1256 6 p.

Research output: Contribution to journalArticle

8 Scopus citations
2012

A phase II study of gemcitabine in combination with tanespimycin in advanced epithelial ovarian and primary peritoneal carcinoma

Wahner Hendrickson, A. E., Oberg, A. L., Glaser, G., Camoriano, J. K., Peethambaram, P. P., Colon-Otero, G., Erlichman, C., Ivy, S. P., Kaufmann, S. H., Karnitz, L. M. & Haluska, P., Feb 1 2012, In : Gynecologic oncology. 124, 2, p. 210-215 6 p.

Research output: Contribution to journalArticle

16 Scopus citations

Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies

Gupta, M., Wahner Hendrickson, A. E., Yun, S. S., Han, J. J., Schneider, P. A., Koh, B. D., Stenson, M. J., Wellik, L. E., Shing, J. C., Peterson, K. L., Flatten, K. S., Hess, A. D., Smith, B. D., Karp, J. E., Barr, S., Witzig, T. E. & Kaufmann, S. H., Jan 12 2012, In : Blood. 119, 2, p. 476-487 12 p.

Research output: Contribution to journalArticle

74 Scopus citations
2009

Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: Effect of the dual-receptor inhibitor BMS-536924 in vitro

Hendrickson, A. E. W., Haluska, P., Schneider, P. A., Loegering, D. A., Peterson, K. L., Attar, R., Smith, B. D., Erlichman, C., Gottardis, M., Karp, J. E., Carboni, J. M. & Kaufmann, S. H., Oct 1 2009, In : Cancer research. 69, 19, p. 7635-7643 9 p.

Research output: Contribution to journalArticle

38 Scopus citations
2006

Porcine endothelial cells and iliac arteries transduced with AdenoIL-4 are intrinsically protected, through Akt activation, against immediate injury caused by human complement

Black, S. M., Grehan, J. F., Rivard, A. L., Benson, B. A., Wahner, A. E., Koch, A. E., Levay-Young, B. K. & Dalmasso, A. P., Nov 15 2006, In : Journal of Immunology. 177, 10, p. 7355-7363 9 p.

Research output: Contribution to journalArticle

Open Access
19 Scopus citations
2004

Progression of chronic myeloid leukemia to blast crisis during treatment with imatinib mesylate

Xu, Y., Wahner, A. E. & Nguyen, P. L., Sep 1 2004, In : Archives of Pathology and Laboratory Medicine. 128, 9, p. 980-985 6 p.

Research output: Contribution to journalArticle

10 Scopus citations
2001

Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo

Wallace, P. K., Kaufman, P. A., Lewis, L. D., Keler, T., Givan, A. L., Fisher, J. L., Waugh, M. G., Wahner, A. E., Guyre, P. M., Fanger, M. W. & Ernstoff, M. S., Feb 1 2001, In : Journal of Immunological Methods. 248, 1-2, p. 167-182 16 p.

Research output: Contribution to journalArticle

17 Scopus citations
2000

Human monocytes express CD163, which is upregulated by IL-10 and identical to p155

Sulahian, T. H., Högger, P., Wahner, A. E., Wardwell, K., Goulding, N. J., Sorg, C., Droste, A., Stehling, M., Wallace, P. K., Morganelli, P. M. & Guyre, P. M., Jan 1 2000, In : Cytokine. 12, 9, p. 1312-1321 10 p.

Research output: Contribution to journalArticle

215 Scopus citations
1998

The role of CD8+ CD40L+ T cells in the formation of germinal centers in rheumatoid synovitis

Wagner, U. G., Kurtin, P. J., Wahner, A., Brackertz, M., Berry, D. J., Goronzy, J. J. & Weyand, C. M., Dec 1 1998, In : Journal of Immunology. 161, 11, p. 6390-6397 8 p.

Research output: Contribution to journalArticle

107 Scopus citations